Casting Light on Evidence  by Rees, Jonathan L.
COMMENTARY
1570 Journal of Investigative Dermatology (2007), Volume 127
See related article on pg 1641
Casting Light on Evidence
Jonathan L. Rees1
Clinicians are growing inured to the fact that rarely do the results of a single 
randomized controlled trial (RCT) decisively change clinical practice. Nor 
should they. In a new RCT, Kirke and colleagues have compared the therapeu-
tic effects of different types of UVB radiation on clearance of psoriasis. Their 
study is unlikely to be the last word on this topic.
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Not long ago, in an age of optimism 
(and statistical naiveté), it seemed that 
you could read the results of a ran-
domized controlled trial (RCT) at the 
weekend and change your prescribing 
habits accordingly on Monday morn-
ing. It was as though the RCT was 
a truth machine: you just fed in the 
patients’ details, added a little random-
ization, mechanically applied some 
statistical test, and out popped a God’s-
eye view of how the Universe worked. 
A veritable epistemological engine. 
Things do not seem quite so simple 
anymore. Indeed, in a recent article, 
Ioannidis (2005) argued cogently, if a 
little mischievously, that the results of 
most clinical studies, including RCTs, 
were mistaken. With this in mind, 
what are we to make of the report by 
Kirke et al. (2007, this issue) that there 
is no difference in efficacy between 
narrowband phototherapy and (selec-
tive) broadband UVB lamps for the 
treatment of psoriasis? Should those 
recently purchased narrowband cabi-
nets be put to one side?
The use of UVB phototherapy to 
treat psoriasis has a long history, but 
it is probably only since the introduc-
tion of psoralen plus UVA (PUVA) 
that interest has focused on how this 
older modality of therapy could be 
made more efficacious. Subsequent 
clinical application has owed more 
to incremental improvement than to 
any “eureka” moments. However, 
if there was an elegant experiment, 
rather than the brute force of clinical 
trials, it was that reported by Parrish 
and Jaenicke in this journal in 1981 
(Parrish and Jaenicke, 1981). In this 
study, Parrish and Jaenicke exposed 
psoriatic plaques to monochromatic 
sources and showed that wavelengths 
less than 290 nm were erythemogen-
ic but had little efficacy. The implica-
tion was that it would be better to use 
lamps of longer wavelengths with the 
UVC filtered out. Although the exact 
relative efficacy of different longer 
UVB wavelengths was unclear, the 
invention of the 311 nm (Philips TL-
01) lamp soon led to their widespread 
use, at least in Europe. In a pattern 
common to the way many medical 
innovations are adopted, an appar-
ent physiological rationale, coupled 
with a few initial small-scale reports 
and enthusiasm by early adopters, 
led to widespread changes in clinical 
practice. Which is where the exem-
plary study by Kirke et al. (2007) 
comes into play. Is there anything spe-
cial about TL-01, or is it just that UVB 
lamps contaminated with UVC are 
less efficacious?
Kirke and colleagues (2007) 
screened 192 subjects in a single uni-
versity hospital center, of whom 124 
were eligible and 24 declined to par-
ticipate. The remaining 100 were ran-
domized, 50 in each group, to receive 
either TL-01 or (selective) UVB with 
UV6 fluorescent lamps. (UV6 bulbs 
have negligible output in the UVC 
range; see Kirke et al. (2007) for a 
comparison of the spectra of the two 
tube types.) The primary outcome was 
the number of treatments to clearance, 
and the proportion of patients clearing 
was also reported. The median num-
ber of exposures was 28.4 for TL-01 
and 30.4 for UV6. With TL-01, 56% of 
patients cleared, whereas with UV6, 
40% cleared. Neither of these com-
parisons was significant at the con-
ventional statistical level. So, in the 
light of the general claims by Ioannidis 
(2005), how do we interpret the data 
from this study as evidence? What 
does it mean?
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First, the failure to find a differ-
ence does not mean one doesn’t exist. 
Perhaps if the study had been larger the 
authors would have found a difference. 
Perhaps. On the other hand, the authors 
cite the usual power calculations, and, 
as with most contemporary clinical tri-
als, the data have been reported in a 
particular frequentist way: that is, you 
first assume no difference, and then 
argue that if an extreme event beyond 
a particular critical value occurs, your 
initial hypothesis is to be rejected. If 
you fail to achieve this critical value, 
you say there are no good grounds 
for rejecting your initial hypothesis. 
We go from hypothesis to data, not 
data to hypothesis (Goodman, 1999a; 
Goodman, 1999b; Royall, 1997). Do 
the results mean that the two treatments 
are equivalent (as in an equivalence 
trial)? The answer is no; the trial was 
not designed to answer this question. 
But if we step outside a strict Neyman–
Pearson frequentist interpretation of the 
results, what do we think? Are the data 
still compatible with TL-01 being more 
efficacious than UV6? Answer: yes. Are 
the data compatible with UV6 being 
more efficacious? Answer: yes. Indeed, 
the answer to these seeming paradoxes 
is that you can only interpret the trial 
as evidence in favor of one particular 
hypothesis over another in the light of 
what you thought before the trial was 
carried out. The trial results should shift 
your prior opinion, but whether the 
conclusion is decisive depends on how 
extreme your viewpoint was before the 
study. If you were fairly indifferent to 
which UVB modality was more effica-
cious, the study provides little reason 
to change this viewpoint. However, if, 
for whatever reason, you were con-
vinced that TL-01 was more effica-
cious, then the study will not convert 
you — but it should lessen your cer-
tainty. It is for these reasons that trials 
are not truth machines and the ghost 
of judgment cannot be exorcised. 
As Ioannidis (2005) and others have 
concluded (Vandenbroucke, 1997), 
one reason trials are not as informa-
tive as we would like is that often we 
go into them with a very weak prior 
hypothesis of what is going on. In these 
circumstances, imbuing rare events 
with biological significance may 
be misleading. Nor should we blame 
the statistician.
But there are other issues, possi-
bly even more important ones, than 
arguments about how to interpret sta-
tistical tests. As has been commented 
on before, many RCTs are extremely 
poor surveys (Kravitz et al., 2004; 
Longford and Nelder, 1999). That is 
to say, it is unclear how representa-
tive the patients studied in a trial are 
of the larger target population. Unlike 
in many studies reported in dermatol-
ogy in which very few patients from a 
particular center are enrolled, in the 
study by Kirke et al. (2007) a very high 
proportion of the patients from their 
center were recruited. It would seem 
likely to me that the patients studied 
are very similar to the ones I see in 
my phototherapy clinic. By contrast, 
in many multicenter studies one sus-
pects that the patients chosen to take 
part are very atypical. Unfortunately, 
such considerations, because they are 
hard (but not impossible) to formalize, 
tend to get neglected in many reviews. 
An RCT on a small nonrandom sample 
may be more misleading as evidence 
than a larger observational study that 
enrolls most subjects within a defined 
geographical population.
Another issue, much discussed by 
Kirke et al. (2007), relates to safety. 
Again, in paying too much attention to 
statistical testing, we may be accused, 
like the proverbial drunk, of search-
ing for our lost keys under the light 
because that is where we can see. 
Numbers have a habit of trumping 
judgment even when they shouldn’t. 
Kirke et al. (2007) correctly state that 
we have no robust data on the safety of 
TL-01 (nor, for that matter, UV6). Trials 
in the particular context of psoriasis 
often cannot measure what some of us 
consider the biggest hazard — cancer, 
although in this case our anxieties are 
somewhat lessened, as the treatments 
are topical. Because there are no direct 
data germane to this issue, the authors 
reasonably use extant data on the rela-
tion between wavelength and skin can-
cer to argue that TL-01 lamps are likely 
to be more hazardous than UV6 tubes. 
Although I cannot dispute their figures, 
I do not find this a decisive reason to 
favor UV6, but, on the other hand, nor 
do I believe that we will ever get clean 
long-term data on the hazards of UV 
in psoriasis without the confounding 
effects of personal sun exposure or sys-
temic medication. If there is a big dif-
ference, we might see it; otherwise, we 
will probably remain ignorant.
So if today is Saturday, what should I 
learn for Monday? First, RCTs are very 
much operational research — health 
technology assessment — rather than 
science. They are often noisy and cum-
bersome, even when they are as good 
as the one under discussion. Second, I 
hope somebody goes back and revisits 
the earlier work of Parrish and Jaenicke 
(1981). As for therapy, I will carry on as 
before: I am not convinced that there is 
much special about TL-01 beyond the 
absence of UVC. Sadly, we now need 
some more trials to prove me wrong.
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